US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Century Therapeutics, Inc. - Common Stock
(NQ:
IPSC
)
1.530
-0.080 (-4.97%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Century Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
October 02, 2026
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Appoints Joseph Truitt to Board of Directors
September 09, 2026
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
August 12, 2026
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026
July 09, 2026
From
Century Therapeutics, Inc.
Via
GlobeNewswire
New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
June 08, 2026
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Reports First Quarter Financial Results and Business Updates
May 13, 2026
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions
April 30, 2026
CNTY-813 is an iPSC-derived islet cell replacement therapy engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes; on track for IND submission in 4Q 2026
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates
March 12, 2026
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics to Participate in Upcoming Investor Conferences in March
February 25, 2026
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes
January 08, 2026
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors
December 09, 2025
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 13, 2025
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes
November 13, 2025
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference
October 14, 2025
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
August 22, 2025
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 14, 2025
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress
May 28, 2025
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 15, 2025
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting
April 28, 2025
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025
April 15, 2025
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
March 19, 2025
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders
January 21, 2025
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
November 26, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 05, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting
November 05, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
November 04, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer
September 26, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 08, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting
June 03, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
